2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 737

A Paper Patient-Based Flare Study in SLE
Abstract Number: 491

A Paradigm Shift in the Disease Assessment of Rheumatoid Arthritis : From Blood to Urine Testing
Abstract Number: 2749

A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-CSF1R) Antibody in Patients (pts) with Rheumatoid Arthritis (RA): Preliminary Results
Abstract Number: 972

A Phase 2b Study Evaluating the Efficacy and Safety of Subcutaneously Administered Tregalizumab in Subjects with Active Rheumatoid Arthritis (RA) Despite Treatment with Methotrexate (MTX)
Abstract Number: 2055

A Phase III, Randomized, Double-Blind Clinical Study Comparing SB4, an Etanercept Biosimilar, with Etanercept Reference Product (Enbrel®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (52-week Results)
Abstract Number: 8L

A Phase III, Randomized, Double-Blind Clinical Study Comparing SB5, an Adalimumab Biosimilar, with Adalimumab Reference Product (Humira®) in Patients with Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy (24-week Results)
Abstract Number: 2858

A Phosphodiesterase 4 Inhibitor for Psoriatic Arthritis: Systematic Review and Meta-Analysis
Abstract Number: 2538

A Population-Based Assessment of Induced Abortions in Women with Systemic Lupus Erythematosus
Abstract Number: 1470

A Population-Based Study of Outcomes of Patients with Juvenile Idiopathic Arthritis (JIA) Compared to Non-JIA Subjects
Abstract Number: 1054

A Potential Role of Type III Interferon in the Glandular Involvement of Sjögren’s Syndrome
Abstract Number: 2108

A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Abstract Number: 150

A Preliminary Consensus on Core Outcome Domains for Total Joint Replacement Clinical Trials: An Omeract-Based Study
Abstract Number: 1110

A Proliferative Inducing Ligand (APRIL) Promotes IL-10 Production of Human B Cells
Abstract Number: 782

A Proposal for Assessing Systemic Lupus Erythematosus Activity By a Multimodal Instrument That Includes Clinical Variables, Physician Assessment and Modification of Treatment
Abstract Number: 998

A Psychometric Analysis of the Social Interaction Anxiety Scale (SIAS-6) in Systemic Sclerosis: Results from the Scleroderma Patient-Centered Intervention Network (SPIN) Cohort

« Previous Page
1
…
4
5
6
7
8
…
218
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].